NewAmsterdam Pharma Company NV has announced a new compensation agreement for Dr. John Kastelein, the company's Chief Scientific Officer and director. Effective from July 1, 2025, this amended and restated Employment Agreement replaces the previous one dated November 18, 2022. Under the new terms, if Dr. Kastelein's employment is terminated without cause, he will receive a severance package including 12 months of his base salary, any earned or payable bonuses, and a prorated bonus for the year of termination. Additionally, should his termination occur related to a change in control, his time-based stock options and equity awards will be accelerated, making them fully exercisable or nonforfeitable, with an extended exercise period for certain options. These changes reflect significant enhancements to Dr. Kastelein's compensation and benefits package.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。